← All trials
NCT01646437
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2012
- Primary completion
- Jun 1, 2019
- Completion date
- Mar 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 5000
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- McMaster UniversityLead sponsor
- St. John's Research InstituteOverall official - principal investigator
- McMaster UniversityOverall official - principal investigator
- Wellcome TrustCollaborator
- Canadian Institutes of Health Research (CIHR)Collaborator
- McMaster UniversityReponsible party - principal investigator
- Cadila HealthcareCollaborator
- Heart and Stroke Foundation of CanadaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.